Targeting the JAK2/STAT3 axis in Alzheimer's disease

• Published in: Expert opinion on therapeutic targets Vol. 13; no. 10; p. 1155
• Main Authors: Chiba, Tomohiro, Yamada, Marina, Aiso, Sadakazu
• Format: Journal Article
• Language: English
• Published: England 01.10.2009
• Subjects: Alzheimer Disease - drug therapy; Humans; Janus Kinase 2 - metabolism; Neuroprotective Agents - pharmacology; STAT3 Transcription Factor - metabolism
• ISSN: 1744-7631
• DOI: 10.1517/14728220903213426

Amyloid beta (Abeta) has long been implicated in the pathogenesis of Alzheimer's disease (AD). Little is known, however, about the intracellular events in neurons which lead to memory loss related to AD. Focusing on the fact that an AD-specific neuroprotective peptide named humanin (HN) inhibits AD-related neurotoxicity by activating the JAK2/STAT3 signaling axis, we recently found that age- and disease-dependent deterioration in the JAK2/STAT3 axis plays a critical role in the pathogenesis of AD. Here we summarize the neuroprotective effect of HN and its derivative, named colivelin (CLN), and also review the roles of the JAK2/STAT3 axis in memory impairment related to AD. The JAK2/STAT3 axis is a major transducer of HN-mediated neuroprotective activity. Abeta-dependent inactivation of the JAK2/STAT3 axis in hippocampal neurons causes cholinergic dysfunction via pre- and post-synaptic mechanisms, which leads to memory impairment related to AD. This provides not only a novel pathological hallmark of AD but also a novel target in AD therapy.